Evaluation of the Aurora Xi New Nomogram Software 2.0
Completed · Not applicable
Conditions studied: Apheresis Related Hypotension
In brief
A clinical trial to evaluate the safety and effectiveness of the Aurora Xi Plasmapheresis System with a new plasma collection volume nomogram.
Key facts
- Study ID
- NCT06122935
- Run by
- Fenwal, Inc.
- People needed
- 6735
- Starts
- 2023-11-27
- Expected to finish
- 2024-05-31
- Last updated by the study team
- 2025-11-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- All subjects must meet current safety guidelines for plasma donation as set forth by the FDA as well as those in the standard operating procedures established by the participating institution.
- Enrolled subjects who do not meet inclusion criteria at a later donation attempt are eligible to remain in the clinical trial and to subsequently donate plasma once they meet eligibility criteria again.
You may not qualify if…
- Subjects not able or unwilling to give consent to participate.
- Subjects withdrawn by a qualified healthcare provider due to safety concerns.
- Subjects who are employed by the clinical site or Sponsor.
Where it is running
- BioLife Plasma Services — Lakeland, Florida, United States
- BioLife Plasma Services — West Des Moines, Iowa, United States
- BioLife Plasma Services — American Fork, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.